We recently published an article titled Why These 10 Firms Nosedived Today.In this article, we are going to take a look at where Lantheus Holdings, Inc. (NASDAQ:LNTH) stands against the other stocks. The stock market bounced back from the previous day’s losses, with all major indices finishing higher as investors cheered the central bank's decision to keep interest rates unchanged. On Wednesday afternoon, the Federal Reserve kept rates steady at a range of 4.25 percent to 4.5 percent, saying that it was not in a hurry to cut rates and could still “wait and see” the impacts of President Donald Trump’s tariff policies. The Dow Jones rallied by 0.70 percent, the S&P 500 increased by 0.43 percent, and the Nasdaq grew by 0.27 percent. Beyond the major indices, bucked a broader market optimism as investors sold off on a series of disappointing news. To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume.Lantheus Holdings, Inc. (LNTH): Among Stocks with Consistent Growth to Buy Now A medical professional performing a pulmonary function assessment on a patient. Lantheus Holdings, Inc. (NASDAQ:LNTH) Lantheus Holdings, Inc. (NASDAQ:LNTH) declined for a third consecutive day on Wednesday, losing 23.23 percent to finish at $80.49 each as investors soured on the company’s lower revenue guidance for the rest of the year, coupled with a disappointing earnings performance. In a statement, Lantheus Holdings, Inc. (NASDAQ:LNTH) said it now expects revenues for full-year 2025 to end between $1.55 billion and $1.585 billion, lower than the $1.545 billion to $1.61 billion as projected previously. Adjusted EPS was also pegged at $6.6 to $6.7 versus the $7 to $7.2 previously. In the first quarter, Lantheus Holdings, Inc. (NASDAQ:LNTH) reported a 44.3 percent lower net income of $72.9 million versus $131.1 million in the same period last year. Revenues also ended at $372.8 million, relatively flat from $370 million in the same comparable period. Lantheus Holdings, Inc. (NASDAQ:LNTH) is one of the leading radiopharmaceutical-focused companies with products across three categories: radiopharmaceutical oncology, precision diagnostics, and strategic partnerships. Overall LNTH ranks 1st on our list of Wednesday's worst performers. While we acknowledge the potential of LNTH as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than LNTH but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. Story Continues READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. View Comments
Why Lantheus Holdings, Inc. (LNTH) Nosedived on Wednesday
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...